Cowen & Co. Keeps a Hold Rating on Chimerix (CMRX)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Chimerix (CMRX) today and set a price target of $3. The company’s shares opened today at $2.87.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.6% and a 49.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.

Chimerix has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.

See today’s analyst top recommended stocks >>

Based on Chimerix’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $14.96 million. In comparison, last year the company had a GAAP net loss of $19.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox.